News and press releases
Follow Resitu's path towards creating a paradigm shift in the management of breast cancer. Read up on news, press releases and clinical studies.
Great interest in the Resitu technology at Lab & Diagnostics meeting
At the conference Lab & Diagnostics for the Future we demonstrated the Resitu Technology to many interested conference visitors by taking samples from a water melon.
ISO certification achieved
Resitu Medical has been certified according to ISO 13485, with the following scope: Design, development, manufacturing and sales of electrosurgical instruments for tissue removal, by DQS Medizinprodukte GmbH. This is a major milestone for the company and now we continue working towards submission of the technical file of our first product.
Sampling in avocado in booth A4 at EBCC
Thanks to everyone who has visited our stand at EBCC. It is soon time to leave Barcelona - but before you do we still have a few avocados left if you have not yet tried the Resitu technology.
At the European Breast Cancer Conference
Discussions in booth A4 at EBCC. Come pay us a visit if you are at the congress.
New seed round closed
Resitu Medical has closed the second seed round of 1.5 MEUR mainly by existing shareholders. Major shareholders are Novoaim 60%, ALMI Invest 15% and Stockholm Business Angels (STOAF) 15%.
The development of the first instrument is proceeding according to plan. The product design is finalized and is currently being transferred to production. “The funding will be used to verification, validation, clinical studies, and prepare the documentation for CE mark and FDA submission” says CEO Stefan Sowa.
Resitu Medical announces new visual identity and website
Resitu Medical is happy to release our new website, presenting our new visual identity. The new identity illustrates our vision: Beyond Conventional surgery and our Mission: We design for a minimal invasive surgical technology. Our new visual identity harmonizes with the user friendliness and intuitive ease of use of our products in development and that our products are designed with the user and the patient in focus. The identity and communication aim to reflect our product message Precision made easy.
Welcome to look around!
Medlim bootcamp
Resitu Medical has been selected as 1 of 16 companies from 68 applicants for the MedLim Matchmaking & Fast Track Acceleration Program. The program is offered to promising startups that develop breakthrough, innovative MedTech products and services in the Cardiovascular, Neurological, Spine & Medical Surgical domains.
EIT health MedTech Accelerator Bootcamp
Resitu Medical was selected for the EIT Health MedTech Accelerator Bootcamp, a six-week online program for promising start-up companies in the medical technology field arranged by EIT Health in collaboration with UnterNehmerThum, IESE Business school and FAU university. The team completed the training guided by mentors and experts covering many aspects of starting and building a business in this challenging field, including medical device regulations, market access, financing, market and competitor analysis, business case and pitch presentation, and the importance of having the right team.
Resitu Medical wins Healthy Longevity Catalyst Award and receives 50 kUSD
Resitu Medical is one of 154 winners selected among 1500 applicants from 50 countries to win the Healthy Longevity Catalyst Award from the US National Academy of Medicine, and receives 50 kUSD. Resitu Medical was selected by EIT Health as 1 of 21 winners from more than 400 applicants in the European Union.
We would like thank the National Academy of Medicine and EIT Health for selecting Resitu Medical as a winner of the Healthy Longevity Catalyst Award. We aim to contribute to health and longevity by enabling correct and early diagnosis and faster treatment of breast cancer. The true winners will be the women with breast lesions and tumours who will get access to the minimally invasive Resitu technology offering them a fast and safe diagnosis giving better treatment outcomes. Our cost effective technology will also bring substantial health economic gains for the benefit of the society.
Almi Invest and STOAF invest in Resitu's new treatment of breast cancer
Almi Invest and STOAF III Scitech invest 2.5 MSEK each in Resitu Medical, for their development of a new instrument for early treatment of breast cancer. Other private investors are also participating in the issue totalling SEK 7.5 million. The money will be used for product development of a version of the instrument ready for CE marking.
€750 000 to EIT Health company Resitu Medical
The medical technology company Resitu Medical AB, working with an innovative solution for tumor biopsies, announced today that Almi Invest, Stockholm Business Angels (STOAF) and private investors have invested €750 000 in the company. The investment will be used to initiate a development project aiming for CE marking in 2023. An additional SEK 20 million will be raised through equity.
Scandinavian startups receiving in total up to €700,000 in funding
Resitu Medical is one of the Scandinavian startups selected for the 2020 annual EIT Health Headstart programme.
89 startups from across Europe of which 14 are based in Scandinavia are selected for support to accelerate the development of promising health solutions